ESR1 and breast carcinoma: Howard et al. proposed that sox11 can stimulate SLUG expression in endocrine-resistant breast cancer by binding to its promoter, leading to the stimulation of epithelial-mesenchymal transition (EMT) and repression of ESR1 expression (31).